Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy With Hydrochlorothiazide Monotherapy in Older Patients With Stage 2 Systolic Hypertension: Results of the ACTION Study

Journal of Clinical Hypertension

Volumn 13, Issue 3, 2011, Pages 162-169

  Basile, Jan ^a   Babazadeh, Simon ^b   Lillestol, Michael ^c   Botha, Jaco ^d   Yurkovic, Carol ^d   Weitzman, Richard ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Crest Clinical Trials Inc   (United States)

^c Lillestol Research LLC   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; HYDROCHLOROTHIAZIDE;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 4 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; STAGE 2 SYSTOLIC HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION;

AGE FACTORS; AGED; AMIDES; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; DISEASE PROGRESSION; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HEALTH STATUS INDICATORS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; SYSTOLE; TREATMENT OUTCOME; UNITED STATES;

EID: 79952186619     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00418.x     Document Type: Article

References (21)

1. Qureshi AI, Suri MF, Kirmani JF, et al. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit. 2005;11:CR403-CR409.
2. Dao HH, Essalihi R, Bouvet C, et al. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005;66:307-317.
3. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308-315.
4. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
5. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
7. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255-3264.
8. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-872.
9. Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc. 2007;55:1056-1065.
10. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
11. Duprez DA, Munger MA, Botha J, et al. Aliskiren for Geriatric Lowering of Systolic Hypertension (AGELESS): a randomized controlled trial. J Hum Hypertens. 2010;24:600-608.
12. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-764.
13. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-2051.
14. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
15. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17:904-910.
16. Calhoun D, Villamil A, Chrysant SG, et al. Antihypertensive efficacy of aliskiren/hydrochlorothiazide (HCT) combinations in patients with stage 2 hypertension: subgroup analysis of a randomized, double-blind, factorial trial. Hypertension. 2008;52:e97 (P209).
17. Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61-73.
18. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17:252-259.
19. Andersen K, Weinberger MH, Constance CM, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2009;10:157-167.
20. Richter D, Mickel C, Acharya S, et al. Aliskiren-based treatment controls blood pressure independent of baseline plasma renin activity. J Hypertens. 2010;28:e429.
21. Sarangapani R, Ebling W, Bush CA, et al. Integrated analysis of PRA, PRC and BP relationship in hypertensive patients on aliskiren treatment: a pooled analysis using data from nine clinical trials. J Hypertens. 2009;27:S143.